ABBV | tickerfilter.com

Fundamental analysis

58%

Profitability 59%

Dept financing 50%

Liquidity 38%

Performance 65%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.53%

1 Month

-0.60%

3 Months

-5.76%

6 Months

-11.96%

1 Year

19.72%

2 Year

21.34%

Key data

Stock price

$203.71

P/E Ratio

94.80

DAY RANGE

$202.84 - $208.33

EPS

$2.37

52 WEEK RANGE

$174.40 - $244.81

52 WEEK CHANGE

$17.22

MARKET CAP

400.607 B

YIELD

2.89%

SHARES OUTSTANDING

1.768 B

DIVIDEND

$1.64

EX-DIVIDEND DATE

10-15-2025

NEXT EARNINGS DATE

07-24-2025

BETA

0.06

PUBLIC FLOAT

AVERAGE 10 VOLUME

$6,571,968

AVERAGE 30 VOLUME

$6,252,498

Company detail

CEO: Richard A. Gonzalez
Region: US
Website: abbvie.com
Employees: 50,000
IPO year: 2013

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism.

ABBV - AbbVie Inc.